Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Capital Expenditures (2020 - 2025)

Legend Biotech filings provide 6 years of Capital Expenditures readings, the most recent being -$5.0 million for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 142.37% to -$5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.6 million, a 60.16% decrease, with the full-year FY2024 number at $14.1 million, down 29.77% from a year prior.
  • Capital Expenditures hit -$5.0 million in Q3 2025 for Legend Biotech, up from -$9.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $35.8 million in Q4 2023 to a low of -$42.2 million in Q4 2021.
  • Median Capital Expenditures over the past 5 years was -$5.4 million (2023), compared with a mean of -$5.3 million.
  • The widest YoY moves for Capital Expenditures: up 271.18% in 2023, down 1990.68% in 2023.
  • Legend Biotech's Capital Expenditures stood at -$42.2 million in 2021, then surged by 50.41% to -$20.9 million in 2022, then skyrocketed by 271.18% to $35.8 million in 2023, then fell by 27.89% to $25.8 million in 2024, then plummeted by 119.38% to -$5.0 million in 2025.
  • The last three reported values for Capital Expenditures were -$5.0 million (Q3 2025), -$9.2 million (Q2 2025), and -$2.0 million (Q1 2025) per Business Quant data.